Skip to main content

Advertisement

Table 1 Baseline characteristics of the rheumatoid arthritis patients a

From: Lack of validation of genetic variants associated with anti–tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis

Baseline characteristics Collection 1 (N= 438) Collection 2 (N= 196)
Age, mean ± SD years 61.0 ± 12.04 56.3 ± 14.77
Age at diagnosis, mean ± SD years 44.95 ± 13.03 42.99 ± 13.69
Females, n (%) 365 (83.3) 160 (81.6)
Disease duration, mean ± SD years 16.45 ± 8.34 12.93 ± 8.47
Rheumatoid factor–positive, n (%) 340 (77.8) 141 (71.94)
Anti-CCP-positive, n (%) 250 (69.6)b 125 (73.1)c
Smoking status, n (%)   
Ever-smoker 51 (16.0)b 20 (13.9)c
Never-smoker 267 (84.0)b 124 (86.1)c
Health status, mean ± SD   
DAS28 at baseline 5.86 ± 1.12 5.36 ± 1.13
Treatment, n (%)   
Concurrent DMARDs 252 (92.6)b 159 (81.1)
Previous biologic agents 0 (0) 14 (10.2)c
Anti-TNF drugs, n (%)   
Infliximab 245 (55.9) 62 (31.6)
Etanercept 113 (25.8) 21 (10.7)
Adalimumab 80 (18.3) 113 (57.7)
EULAR-defined response at 6 months, n (%)   
Responders 337 (80.4) 167 (85.2)
Nonresponders 82 (19.6) 29 (14.8)
EULAR-defined response at 12 months, n (%)   
Responders 259 (82.5) 118 (88.1)
Nonresponders 55 (17.5) 16 (11.9)
  1. aAnti-CCP, Anti–cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; DMARD, Disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; TNF, Tumor necrosis factor. bData are from <85% of the patients: 359 for anti-CCP status, 318 for smoking status and 272 for concurrent DMARD treatment. cData are from <70% of the patients: 171 for anti-CCP status, 144 for smoking status and 137 for previous biologic agent treatment.